X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs BIOCON LTD - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA BIOCON LTD ABBOTT INDIA/
BIOCON LTD
 
P/E (TTM) x 34.9 86.7 40.3% View Chart
P/BV x 9.0 7.3 122.4% View Chart
Dividend Yield % 0.8 0.2 487.2%  

Financials

 ABBOTT INDIA   BIOCON LTD
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
BIOCON LTD
Mar-18
ABBOTT INDIA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs6,1101,188 514.3%   
Low Rs3,996305 1,310.2%   
Sales per share (Unadj.) Rs1,552.268.7 2,258.7%  
Earnings per share (Unadj.) Rs188.87.6 2,500.2%  
Cash flow per share (Unadj.) Rs196.414.0 1,406.0%  
Dividends per share (Unadj.) Rs55.001.00 5,500.0%  
Dividend yield (eoy) %1.10.1 812.5%  
Book value per share (Unadj.) Rs796.686.3 922.6%  
Shares outstanding (eoy) m21.25600.00 3.5%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.310.9 30.0%   
Avg P/E ratio x26.898.9 27.1%  
P/CF ratio (eoy) x25.753.4 48.1%  
Price / Book Value ratio x6.38.6 73.4%  
Dividend payout %29.113.2 220.0%   
Avg Mkt Cap Rs m107,376447,900 24.0%   
No. of employees `0003.36.1 54.0%   
Total wages/salary Rs m3,9379,311 42.3%   
Avg. sales/employee Rs Th9,929.36,705.8 148.1%   
Avg. wages/employee Rs Th1,185.11,514.2 78.3%   
Avg. net profit/employee Rs Th1,207.7736.9 163.9%   
INCOME DATA
Net Sales Rs m32,98541,234 80.0%  
Other income Rs m1,1702,062 56.7%   
Total revenues Rs m34,15543,296 78.9%   
Gross profit Rs m5,2458,291 63.3%  
Depreciation Rs m1623,851 4.2%   
Interest Rs m38615 6.2%   
Profit before tax Rs m6,2155,887 105.6%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2031,569 140.4%   
Profit after tax Rs m4,0124,531 88.5%  
Gross profit margin %15.920.1 79.1%  
Effective tax rate %35.426.7 133.0%   
Net profit margin %12.211.0 110.7%  
BALANCE SHEET DATA
Current assets Rs m22,65541,486 54.6%   
Current liabilities Rs m6,68121,413 31.2%   
Net working cap to sales %48.448.7 99.5%  
Current ratio x3.41.9 175.0%  
Inventory Days Days6564 101.3%  
Debtors Days Days2994 31.0%  
Net fixed assets Rs m83550,661 1.6%   
Share capital Rs m2133,000 7.1%   
"Free" reserves Rs m16,71548,808 34.2%   
Net worth Rs m16,92851,808 32.7%   
Long term debt Rs m017,898 0.0%   
Total assets Rs m24,16299,897 24.2%  
Interest coverage x163.710.6 1,548.3%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.40.4 330.7%   
Return on assets %16.85.2 325.4%  
Return on equity %23.78.7 271.0%  
Return on capital %36.99.6 383.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36912,058 3.1%   
Fx outflow Rs m3,8077,348 51.8%   
Net fx Rs m-3,4384,710 -73.0%   
CASH FLOW
From Operations Rs m1,5276,621 23.1%  
From Investments Rs m-2,148-6,840 31.4%  
From Financial Activity Rs m-1,024-2,397 42.7%  
Net Cashflow Rs m-1,646-2,612 63.0%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 7.9 8.4 94.0%  
FIIs % 0.1 10.7 0.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 19.9 85.9%  
Shareholders   18,270 109,995 16.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  DIVIS LABORATORIES  TTK HEALTHCARE  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Asian Paints Falls on Weak Q2 Result(09:30 am)

Asian stocks are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 2.2% while the Hang Seng is down 2.2%.

Related Views on News

BIOCON LTD Plunges by 5%; BSE HEALTHCARE Index Down 1.1% (Market Updates)

Oct 23, 2018 | Updated on Oct 23, 2018

BIOCON LTD share price has plunged by 5% and its current market price is Rs 672. The BSE HEALTHCARE is down by 1.1%. The top gainers in the BSE HEALTHCARE Index are GLENMARK PHARMA (up 1.3%) and PFIZER (up 1.1%). The top losers is BIOCON LTD (down 5.4%)..

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

You Can Buy Select Auto Stocks Now for Big Long-Term Returns(The 5 Minute Wrapup)

Oct 17, 2018

Irrespective of the earnings hiccups, these businesses be setting new profit records.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Stop! Read This Before You Cancel Your SIPs(Profit Hunter)

Oct 11, 2018

Read this before you stop your SIP's in equity mutual funds.

Even If IL&FS Group Brought This Correction, this is Right Time to Buy & Sit Tight!(Chart Of The Day)

Oct 12, 2018

Even if IL&FS is the culprit, it may turn out to be a hero if you buy right and sit tight.

Why Oil Cannot Be Sold to India in Rupees(Vivek Kaul's Diary)

Oct 16, 2018

Oil is bought and sold internationally in terms of dollars. And any change to this, will be attacking the exorbitant privilege of the US dollar.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Oct 23, 2018 12:25 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS